Skip to main content
. 2024 Oct 19;16(10):1340. doi: 10.3390/pharmaceutics16101340

Figure 5.

Figure 5

Total and unbound lenalidomide concentrations in plasma from three patients after three days of the first cycle containing oral lenalidomide 25 mg or equivalent dose for renally impaired patients. (AC) represent the total and unbound plasma concentrations of lenalidomide in each patient.